These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 5540775)

  • 1. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 2. [Silent period in patients with Parkinson's disease treated with L-Dopa].
    Palao Sánchez A
    Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780
    [No Abstract]   [Full Text] [Related]  

  • 3. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
    Hare TA; Beasley BL; Chambers RA; Boehme DH; Vogel WH
    Clin Chim Acta; 1973 May; 45(3):273-80. PubMed ID: 4708057
    [No Abstract]   [Full Text] [Related]  

  • 4. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 7. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.
    Muenter MD; Tyce GM
    Mayo Clin Proc; 1971 Apr; 46(4):231-9. PubMed ID: 5573818
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of Parkinson's syndrome with L-dopa].
    Ljung O
    Lakartidningen; 1972 Jun; 69(24):2940-4. PubMed ID: 5037135
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 10. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
    Figuerido JA; De la Herrán J
    Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

  • 12. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy.
    Lipman IJ; Papadopoulos NM
    Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
    Hirayama K; Uono M; Nakanishi T; Kato N; Nagao Y
    Shinkei Kenkyu No Shimpo; 1971; 15(1):267-85. PubMed ID: 4937721
    [No Abstract]   [Full Text] [Related]  

  • 16. [L-dopa effect in Parkinson's syndrome].
    Römer F; Bettag W; Bock WJ
    Z Allgemeinmed; 1971 Feb; 47(6):281-3. PubMed ID: 5571715
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
    Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L
    Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373
    [No Abstract]   [Full Text] [Related]  

  • 18. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 20. [Our first observations on Parkinson's disease or parkinsonian syndromes treated with L-dopa].
    Boudouresques J; Khalil R; Vigouroux RA; Gosset A; Daniel F; Dufour H
    Mars Med; 1971; 108(2):85-9. PubMed ID: 5548385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.